Biopharmaceutical Company, Syntaxin announces Dr. Laurence Barker as Head of Business Development

Syntaxin is delighted to announce the appointment of Dr. Laurence Barker to the newly created role of Head of Business Development. Dr. Barker joins Syntaxin from MorphoSys AG where he held the position of Associate Director, Business Development.
Oxford, UK -- As Syntaxin have created this new role to initiate further business deals to aid the research and development of Syntaxin’s technology.

In his previous position, Dr Barker led negotiations and completed several complex licensing deals and strategic collaborations with US, European and Japanese organisations, including those with the large Japanese pharmaceutical companies Daiichi-Sankyo, Astellas and Shionogi. He was also a key member of the MorphoSys team that negotiated and signed the transformational strategic partnership with Novartis in 2007. Prior to MorphoSys, Dr. Barker was Project Manager at Sympore GmbH, a private drug discovery company, where he led a multidisciplinary project team within research and early development of biopharmaceuticals.

At Syntaxin, Dr. Barker will assume responsibility for the implementation of the business development and commercial strategies surrounding the Syntaxin’s proprietary re-targeted endopeptidase discovery platform. He has an MSc in Biochemistry and Cellular & Molecular biology from the University of Auckland, New Zealand, a PhD in biochemistry and molecular biology from the Eberhard-Karls University of Tübingen, Germany, and an MBA from the Judge Business School, Cambridge University.

Patrick Doyle, CEO of Syntaxin, said: “We are delighted to welcome Laurence to the Syntaxin team. He brings an impressive track record in business development particularly in innovative platform technologies and this will be of great benefit to the Company as we look to strengthen and expand our growing business development efforts.”
For more information on biopharmaceuticals or on Syntaxin’s work, visit
http://www. syntaxin.com.
**ENDS**

About Syntaxin:
Syntaxin Ltd is a biotech company that designs and develops novel drugs for the treatment of cell secretion.

Cell secretion plays an important role in the development of numerous diseases including respiratory, endocrine, inflammatory and oncology. Syntaxin’s proprietary technology uses an innovative approach to treating these diseases by enabling the production of proteins with broad therapeutic applicability. Syntaxin’s unique science selectively shuts down stimulated vesicular secretion in a cell that causes disease by using the novel recombinant proteins developed through the genetic engineering process of its novel proprietary technology. Exciting future benefits of this exclusive approach include the combination of high potency, broad safety and improved efficacy together with a long duration of action providing infrequent dosing requirements.

Press Contact:
Syntaxin Ltd
Units 4-10, The Quadrant
Barton Lane
Abingdon
Oxon
OX14 3YS

Tel: +44 (0) 1235 552100
Fax: +44 (0) 1235 552200
Email: info@syntaxin.com

This release was published on openPR.